Oncology Clinical Trials

Oncology Clinical Trials

10x your market intelligence team

10x your market intelligence team

The agentic AI platform for Life Sciences. Turn noise into strategic advantage.

Evaluated 214 trials

Evaluated 214 trials

Evaluated 214 trials

Flagged Idonescimab Phase III update

Flagged Idonescimab Phase III update

Flagged Idonescimab Phase III update

Benchmarked against Adalimab timeline

Benchmarked against Adalimab timeline

Benchmarked against Adalimab timeline

Generated competitive summary

Generated competitive summary

Generated competitive summary

Took 23 sec

Took 23 sec

Took 23 sec

Just flagged a new Phase II competitor trial that might impact your Q2 strategy.

Just flagged a new Phase II competitor trial that might impact your Q2 strategy.

Just flagged a new Phase II competitor trial that might impact your Q2 strategy.

Ask something

Ask something

Ask something

Sentinel

Sentinel

Sentinel

Add files

Add files

Add files

On it...

On it...

On it...

Pull up the the competitive trial development timeline for my asset in NSCLC.

Pull up the the competitive trial development timeline for my asset in NSCLC.

Pull up the the competitive trial development timeline for my asset in NSCLC.

View Insight Report

View Insight Report

View Insight Report

Processing 122 active trials...

Processing 122 active trials...

Processing 122 active trials...

Took 15 sec

Took 15 sec

Took 15 sec

Miraei AI Ambient Agent

Miraei AI Ambient Agent

Miraei AI Ambient Agent

Strategy Mode: NSCLC | Q2 Planning

Strategy Mode: NSCLC | Q2 Planning

Strategy Mode: NSCLC | Q2 Planning

Built on data from trusted clinical and regulatory sources:

Sentinel

Ask anything about clinical trials

Always on. Always available. Miraei is constantly scanning the market and flagging important events to help answer the questions that keep strategy teams up at night.

Pipeline assets

Pipeline assets

Strategic fit scores across competitors

Strategic fit scores across competitors

CDx gaps, biomarker strategies

CDx gaps, biomarker strategies

. Regulatory timelines

. Regulatory timelines

Long-term goals

Long-term goals

Trial Activity Footprint

Trial Activity Footprint

Recent events

Recent events

Show me a list of all the trials that could potentially use an RNA assay for trial enrollment

Show me a list of all the trials that could potentially use an RNA assay for trial enrollment

Give me a list of all of the attendees for the BIO conference and export it

Give me a list of all of the attendees for the BIO conference and export it

How many assets are seeking early-stage approval in NSCLC?

How many assets are seeking early-stage approval in NSCLC?

What are the top 5 takeaways and trends in CNS oncology from ASCO 2025?

What are the top 5 takeaways and trends in CNS oncology from ASCO 2025?

Show me an efficacy comparison of the top 5 bispecific drugs in phase 2 clinical trials

Show me an efficacy comparison of the top 5 bispecific drugs in phase 2 clinical trials

Which ADC assets are my biggest competitors and how do their PTS rank vs. mine?

Which ADC assets are my biggest competitors and how do their PTS rank vs. mine?

How many phase 3 KRAS drugs are set to achieve regulatory approval within the next 6 months in the USA?

How many phase 3 KRAS drugs are set to achieve regulatory approval within the next 6 months in the USA?

Ask me anything

Ask me anything

Virtuoso

Turn information into implication

Miraei’s agentic analysts serve as a force-multiplier for your teams, continuously gathering information, presenting findings, and translating them into strategic implications.

BMQ327’s Key Signals

BMQ327’s Key Signals

Jun 2025

Jun 2025

$11B co-dev deal with BNS Pharma

$11B co-dev deal with BNS Pharma

May 2025

May 2025

Phase 3 TNBC trial to launch by Q4 2025

Phase 3 TNBC trial to launch by Q4 2025

Apr 2025

Apr 2025

54% ORR with BMQ325 combo in PROC

54% ORR with BMQ325 combo in PROC

Mar 2025

Mar 2025

Multiple combo arms with other ADCs and mRNAs

Multiple combo arms with other ADCs and mRNAs

Feb 2025

Feb 2025

Improved tumor kill with ADC combos in pre-clinical studies

Improved tumor kill with ADC combos in pre-clinical studies

Noticed their ORR outpaces yours — worth watching.

Noticed their ORR outpaces yours — worth watching.

Miraei Virtuoso Insight

Miraei Virtuoso Insight

BMQ327 is being positiong as a modular I/O backbone across solid tumors with multiple combo regimens. Competition in I/O, VEGF, and ADC spaces must reassess positioning against this fast-moving threat.

BMQ327 is being positiong as a modular I/O backbone across solid tumors with multiple combo regimens. Competition in I/O, VEGF, and ADC spaces must reassess positioning against this fast-moving threat.

Suggestions

Suggestions

What other ADC combos are entering trials this year?

What other ADC combos are entering trials this year?

How does their ORR compare to our lead asset?

How does their ORR compare to our lead asset?

Conductor

One command center for all of your strategic needs

Meet the Four Agents Behind Miraei’s Intelligence Layer

Seamlessly integrated, always-on agents working together to deliver ambient strategic insight — exactly when you need it.

Conductor

The orchestrator. Unites all agents into one fluid experience — your primary interface to interact, inquire, and act.

Sentinel

Real-time intelligence gatherer. Constantly scans the competitive landscape, flags meaningful events, and keeps you one step ahead.

Virtuoso

The analyst. Translates noise into clarity by extracting the strategic implications of each signal Sentinel captures.

Composer

Your predictive guide. Suggests next best actions based on deep context, patterns, and your business goals.

Get early access to your AI-powered oncology strategist.

Get early access to your AI-powered oncology strategist.

Get early access to your AI-powered oncology strategist.

© 2025 Miraei. All rights reserved.

Terms and Conditions

Privacy Policy

© 2025 Miraei. All rights reserved.

Terms and Conditions

Privacy Policy

© 2025 Miraei. All rights reserved.

Terms and Conditions

Privacy Policy